Novel, potent anti-androgens of therapeutic potential: Recent advances and promising developments

Future Medicinal Chemistry

Volumn 2, Issue 4, 2010, Pages 667-680

  Vasaitis, Tadas S ^a   Njar, Vincent Co ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b School of Pharmacy   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BMS 501949; BMS 570511; BMS 641988; CYPROTERONE ACETATE; DRUG METABOLITE; EPIRUBICIN; EVEROLIMUS; FLUTAMIDE; GEFITINIB; GONADORELIN AGONIST; LIGAND; MDV 3100; NILUTAMIDE; RU 59063; TESTOSTERONE; TOK 001; UNCLASSIFIED DRUG; VN/124 1;

ALCOHOL INTOLERANCE; ANTIANDROGEN THERAPY; BODY COMPOSITION; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENCY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; ESTROGEN BLOOD LEVEL; FATIGUE; GENE MUTATION; GYNECOMASTIA; HOT FLUSH; HUMAN; INTERSTITIAL PNEUMONIA; LIBIDO DISORDER; LIPID BLOOD LEVEL; LIVER TOXICITY; MASTALGIA; MONOTHERAPY; NAUSEA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; HUMANS; MALE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 77953463770     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.14     Document Type: Review

References (79)

1. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci. 1, 59-71 (1996).
2. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 27(1), 36-41 (2009).
3. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23(2), 175-200 (2002).
4. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 9(3), 601-610 (2002).
5. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin. Cancer Biol. 5(5), 391-400 (1994).
6. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 178(4 Pt. 1), 1290-1295 (2007).
7. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56(6), 1021-1024 (2000).
8. Tammela T. Endocrine treatment of prostate cancer. J. Steroid Biochem. Mol. Biol. 92(4), 287-295 (2004).
9. Labrie F, Cusan L, Gomez JL et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J. Steroid Biochem. Mol. Biol. 113(1-2), 52-56 (2009).
10. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J. Urol. 180(3), 921-927 (2008).
11. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCOR and SMRT corepressors. Cancer Res. 67(17), 8388-8395 (2007).
12. Gaillard-Moguilewsky M. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology 37(Suppl. 2), 5-12 (1991).
13. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem. 7(2), 211-247 (2000).
14. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int. 91(5), 455-461 (2003). (Pubitemid 36359626)
15. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int. 87(1), 47-56 (2001).
16. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J. Clin. Oncol. 25(12), 1596-1605 (2007).
17. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin. Pharmacother. 6(7), 1095-1106 (2005).
18. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61(2 Suppl. 1), 32-38 (2003).
19. Iversen P. Quality of life issues relating to endocrine treatment options. Eur. Urol. 36 (Suppl. 2), 20-26 (1999).
20. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339(15), 1036-1042 (1998).
21. Mcleod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2(1), 18-27 (1997).
22. Schroder FH, Whelan P, De Reijke TM et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European organization for research and treatment of cancer" (EORTC) protocol 30892. Eur. Urol. 45(4), 457-464 (2004).
23. Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch. Ital. Urol. Androl. 71(5), 293-302 (1999).
24. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer. An overview of the randomised trials. Lancet 355(9214), 1491-1498 (2000).
25. Fourcade RO, Mcleod D. Tolerability of antiandrogens in the treatment of prostate cancer. Urooncology 4(1), 5-13 (2004).
26. Heidenreich MB, Joniau S, Van Der Kwast VM et al. Guidelines on prostate cancer. Actas. Urol. Esp. 33(20), 113-126(2009).
27. Nakabayashi M, Bartlett RA, Oh WK. Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. J. Clin. Oncol. 24(18), 2958-2959 (2006).
28. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann. Pharmacother. 31(1), 65-75 (1997).
29. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J. Cancer Res. Clin. Oncol. 132(Suppl. 1), S17-S26 (2006).
30. Labrie F, Dupont A, Belanger A et al. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J. Steroid Biochem. 19(1C), 999-1007 (1983).
31. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 22(2), 331-340 (2008).
32. Akaza H, Yamaguchi A, Matsuda T et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in japanese patients. Japan J. Clin. Oncol. 34(1), 20-28 (2004).
33. Akaza H, Hinotsu S, Usami M et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a Phase III, double-blind, randomized study for survival. Cancer 115(15), 3437-3445 (2009).
34. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. Int. J. Urol. 14(3), 264-267 (2007).
35. Francini G, Paolelli L, Francini E et al. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur. J. Surg. Oncol. 34(2), 216-221 (2008).
36. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol. 164(5), 1579-1582 (2000).
37. Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. J. Urol. 170(6;2), S48-52; discussion S52-44 (2003).
38. Wirth M, Tyrrell C, Delaere K et al. Bicalutamide (casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from early prostate cancer trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis. 10(1), 87-93 (2007).
39. Smith MR, Goode M, Zietman AL, Mcgovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J. Clin. Oncol. 22(13), 2546-2553 (2004).
40. Suzuki H, Kamiya N, Imamoto T et al. Current topics and perspectives relating to hormone therapy for prostate cancer. Int. J. Clin. Oncol. 13(5), 401-410 (2008).
41. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 69(4), 1243-1254 (2009).
42. Holzbeierlein J, Lal P, Latulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164(1), 217-227 (2004).
43. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66(5), 2815-2825 (2006).
44. Yu YP, Landsittel D, Jing L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22(14), 2790-2799 (2004).
45. Mohler JL, Gregory CW, Ford OH 3rd et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10(2), 440-448 (2004).
46. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67(10), 5033-5041 (2007).
47. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 10(21), 7121-7126 (2004). (Pubitemid 39487695)
48. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 171(2;1), 679-683 (2004).
49. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 149(3), 607-609. (1993).
50. Fenton MA, Shuster TD, Fertig AM et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 3(8), 1383-1388 (1997).
51. Veldscholte J, Ris-Stalpers C, Kuiper GG et al. A mutation in the ligand binding domain of the androgen receptor of human LNCAP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173(2), 534-540 (1990).
52. Taplin ME, Rajeshkumar B, Halabi S et al. Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group b study 9663. J. Clin. Oncol. 21(14), 2673-2678 (2003).
53. Yoshida T, Kinoshita H, Segawa T et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65(21), 9611-9616 (2005).
54. Terada N, Shimizu Y, Yoshida T et al. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate 70(3), 252-261 (2009).
55. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second-line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 169(5), 1742-1744 (2003).
56. Geller J, De La Vega DJ, Albert JD, Nachtsheim DA. Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J. Clin. Endocrinol. Metab. 58(1), 36-40 (1984).
57. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology 72(2), 247-254 (2008).
58. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9(4), 401-406 (1995).
59. Hobisch A, Hittmair A, Daxenbichler G et al. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J. Pathol. 182(3), 356-361 (1997).
60. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10(1), 33-39 (2004).
61. Brown RS, Edwards J, Dogan A et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 198(2), 237-244 (2002).
62. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89(3), 552-556 (2003).
63. Gregory CW, He B, Johnson RT et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61(11), 4315-4319. (2001).
64. Han G, Buchanan G, Ittmann M et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl Acad. Sci. USA 102(4), 1151-1156 (2005).
65. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, Devere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes casodex-induced growth inhibition in casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 26(41), 6061-6070 (2007).
66. Yuan X, Li T, Wang H et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am. J. Pathol. 169(2), 682-696 (2006).
67. Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin. Cancer Res. 15(1), 39-47 (2009).
68. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23(32), 8253-8261 (2005).
69. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
70. Scher TMB, Higano, Taplin E et al. Prostate Cancer Clinical Trials Consortium. Antitumor activity of MDV3100 in a Phase I/II study of castration-resistant prostate cancer (CRPC). ASCO Meeting Abstracts 27, 5011 (2009).
71. Salvati Me, Balog A, Shan W et al. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Bioorg. Med. Chem. Lett. 18(6), 1910-1915 (2008).
72. Culig Z, Hoffmann J, Erdel M et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81(2), 242-251 (1999).
73. Attar RM, Jure-Kunkel M, Balog A et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 69(16), 6522-6530 (2009).
74. Handratta VD, Vasaitis TS, Njar VC et al. Novel c-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48(8), 2972-2984 (2005).
75. Vasaitis T, Belosay A, Schayowitz A et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{a}- hydroxylase/17,20-lyase inhibitor 3b-hydroxy-17-(1h-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer. Mol. Cancer Ther. 7(8), 2348-2357 (2008).
76. Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther. 7(1), 121-132 (2008).
77. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/ coactivator disruptors. ACS Chem. Biol. 4(6), 435-440 (2009).
78. Jones JO, Bolton EC, Huang Y et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc. Natl Acad. Sci. USA 106(17), 7233-7238 (2009).
79. Jones JO, Diamond MI. A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem. Biol. 3(7), 412-418 (2008).